Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Phase 1/2 Recruiting
97 enrolled
ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
120 enrolled
A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
Phase 1/2 Recruiting
43 enrolled
A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
Phase 1/2 Recruiting
8 enrolled
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
Phase 1/2 Recruiting
155 enrolled
A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
Phase 1/2 Recruiting
606 enrolled
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Phase 1/2 Recruiting
160 enrolled
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
Phase 1/2 Recruiting
28 enrolled
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Phase 1/2 Recruiting
96 enrolled
A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)
Phase 1/2 Recruiting
40 enrolled
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
116 enrolled
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
Phase 1/2 Recruiting
29 enrolled
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
Phase 1/2 Recruiting
320 enrolled
CAVALRY
Phase 1/2 Recruiting
104 enrolled
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
Phase 1/2 Recruiting
50 enrolled
ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
42 enrolled
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Phase 1/2 Recruiting
64 enrolled
A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax
Phase 1/2 Recruiting
31 enrolled
Avo In R/R And Previously Untreated MCL
Phase 1/2 Recruiting
72 enrolled
Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
Phase 1/2 Recruiting
73 enrolled
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
Phase 1/2 Recruiting
250 enrolled
Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
84 enrolled
Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms
Phase 1/2 Recruiting
62 enrolled
Study to Evaluate the Safety and Tolerability of EP0042
Phase 1/2 Recruiting
70 enrolled
AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
78 enrolled
Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 1/2 Recruiting
249 enrolled
HEM-iSMART C
Phase 1/2 Recruiting
26 enrolled
HEM-iSMART B
Phase 1/2 Recruiting
26 enrolled
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
Phase 1/2 Recruiting
39 enrolled
TUSCANY
Phase 1/2 Recruiting
240 enrolled
Decitabine and Venetoclax Treatment as Maintenance Therapy in Patients Post Allograft Stem Cell Transplant
Phase 1/2 Recruiting
20 enrolled
Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Phase 1/2 Recruiting
12 enrolled
Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis
Phase 1/2 Recruiting
53 enrolled
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
Phase 1/2 Recruiting
82 enrolled
BELI(E)VE
Phase 1/2 Recruiting
45 enrolled
BN104 in Combination With Chemotherapy or Targeted Agents for Acute Myeloid Leukemia
Phase 1/2 Recruiting
135 enrolled
Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML
Phase 1/2 Recruiting
38 enrolled
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Phase 1/2 Recruiting
70 enrolled